The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to physicians in all settings. With very few exceptions, the prevailing narrative has gone unchallenged. This paper provides a more in-depth and balanced look into the evidence supporting the current narrative and presents suggested actions biopharmaceutical companies should take in response to increasing access restrictions of sales reps to physicians.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Fill in your details to get a copy of this whitepaper, and contact us at email@example.com for any questions.